NCT04038957View on ClinicalTrials.gov

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 7, 2019

Primary Completion Date

June 6, 2023

Study Completion Date

June 6, 2023

Conditions
Schizophrenia
Interventions
DRUG

SEP-363856

SEP-363856 50mg, 75mg flexable dosing, dosed once daily capsule

Trial Locations (1)

Unknown

Research Site, London

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT04038957 - A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging | Biotech Hunter | Biotech Hunter